{"id":61202,"date":"2026-03-25T12:48:36","date_gmt":"2026-03-25T04:48:36","guid":{"rendered":"https:\/\/flcube.com\/?p=61202"},"modified":"2026-03-25T12:48:36","modified_gmt":"2026-03-25T04:48:36","slug":"kelun-biotech-reports-2025-revenue-rmb-2-06-billion-four-drugs-commercialized-30-pipeline-assets-drive-diversification","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61202","title":{"rendered":"Kelun\u2011Biotech Reports 2025 Revenue RMB 2.06 Billion \u2013 Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6990:HKG\">HKG: 6990<\/a>) announced <strong>annual results for 2025<\/strong>, with <strong>full\u2011year revenue reaching RMB 2.058 billion<\/strong> (\u2248\u202fUS$298 million) and <strong>gross profit of RMB 1.479 billion<\/strong> (\u2248\u202fUS$214 million), while advancing a <strong>differentiated R&amp;D pipeline<\/strong> spanning <strong>bispecific ADCs, radionuclide drug conjugates (RDCs), immune\u2011stimulating ADCs (iADCs), and degrader\u2011antibody conjugates (DACs)<\/strong> \u2013 positioning the company for <strong>business transformation from clinical\u2011stage to commercial\u2011stage biopharma<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-fy2025\">Financial Performance \u2013 FY2025<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>FY2025<\/th><th>USD Equivalent<\/th><th>Strategic Context<\/th><\/tr><\/thead><tbody><tr><td><strong>Revenue<\/strong><\/td><td>RMB 2.058 billion<\/td><td>US$298 million<\/td><td>Commercial traction with four marketed drugs<\/td><\/tr><tr><td><strong>Gross Profit<\/strong><\/td><td>RMB 1.479 billion<\/td><td>US$214 million<\/td><td>71.9% gross margin \u2013 biologics premium pricing<\/td><\/tr><tr><td><strong>Reported Loss<\/strong><\/td><td>RMB 382 million<\/td><td>US$55.41 million<\/td><td>Investment phase in pipeline expansion<\/td><\/tr><tr><td><strong>Adjusted Loss<\/strong><\/td><td>RMB 211 million<\/td><td>US$30.61 million<\/td><td>Excludes non\u2011recurring items; improving trajectory<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-portfolio-four-approved-drugs\">Commercial Portfolio \u2013 Four Approved Drugs<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Generic Name<\/th><th>Indication\/Class<\/th><th>NRDL Status (2025)<\/th><\/tr><\/thead><tbody><tr><td><strong>Jiatailai<\/strong><\/td><td>Sacituzumab tirumotecan<\/td><td>TROP2 ADC \u2013 breast cancer<\/td><td><strong>Included<\/strong><\/td><\/tr><tr><td><strong>Shutailai<\/strong><\/td><td>Trastuzumab botidotin<\/td><td>HER2 ADC \u2013 breast cancer<\/td><td><strong>Included<\/strong><\/td><\/tr><tr><td><strong>Ketailai<\/strong><\/td><td>Tagitanlimab<\/td><td>PD\u2011L1 inhibitor \u2013 multiple indications<\/td><td><strong>Included<\/strong><\/td><\/tr><tr><td><strong>Datailai<\/strong><\/td><td>Cetuximab N01<\/td><td>EGFR mAb \u2013 colorectal cancer<\/td><td>Not specified<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NRDL Coverage:<\/strong> <strong>3 products, 5 indications<\/strong> included in 2025 National Reimbursement Drug List \u2013 critical for hospital access and volume scaling<\/li>\n\n\n\n<li><strong>Strategic Achievement:<\/strong> <strong>Full\u2011chain ecosystem<\/strong> \u2013 R&amp;D to commercialization validation<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-r-amp-d-pipeline-next-generation-modalities\">R&amp;D Pipeline \u2013 Next\u2011Generation Modalities<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Modality<\/th><th>Technology Focus<\/th><th>Strategic Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Bispecific ADCs<\/strong><\/td><td>Dual\u2011target antibody\u2011drug conjugates<\/td><td>Tumor\u2011targeted payload + immune modulation (e.g., SKB103 TAA\u2011PD\u2011L1)<\/td><\/tr><tr><td><strong>RDCs<\/strong><\/td><td>Radionuclide drug conjugates<\/td><td>Targeted radiotherapy for solid tumors<\/td><\/tr><tr><td><strong>iADCs<\/strong><\/td><td>Immune\u2011stimulating ADCs<\/td><td>Immunogenic cell death + payload delivery<\/td><\/tr><tr><td><strong>DACs<\/strong><\/td><td>Degrader\u2011antibody conjugates<\/td><td>PROTAC payload delivery for protein degradation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Scale:<\/strong> <strong>30+ drug candidates<\/strong>; <strong>10+ in clinical stage<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Expansion:<\/strong> Beyond oncology into <strong>autoimmune diseases<\/strong> and <strong>metabolic disorders<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-strategic-outlook\">Market Impact &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Growth Trajectory:<\/strong> RMB 2.06 billion revenue represents <strong>~35\u201140% YoY growth<\/strong> (estimated); NRDL inclusion drives <strong>volume expansion<\/strong> in 2026\u20112027; four\u2011product commercial portfolio supports <strong>RMB3\u20114 billion<\/strong> annual revenue target by 2027\u20112028.<\/li>\n\n\n\n<li><strong>Margin Expansion Potential:<\/strong> 71.9% gross margin with <strong>manufacturing scale\u2011up<\/strong> and <strong>biosimilar\/ADC platform efficiencies<\/strong>; path to <strong>operating breakeven 2027\u20112028<\/strong> assuming pipeline advancement without major dilutive financing.<\/li>\n\n\n\n<li><strong>Platform Diversification Strategy:<\/strong> <strong>OptiDC platform<\/strong> (ADC backbone) enables <strong>modular expansion<\/strong> into RDC, iADC, DAC formats; <strong>non\u2011oncology diversification<\/strong> (autoimmune, metabolic) reduces oncology\u2011concentration risk; <strong>global competitiveness<\/strong> positioning through differentiated modalities.<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> vs. <strong>RemeGen<\/strong> (TROP2 ADC focus) \u2013 Kelun\u2011Biotech broader modality diversity; vs. <strong>Henlius<\/strong> (biosimilar\u2011heavy) \u2013 Kelun\u2011Biotech innovation\u2011focused; <strong>SKB103 bispecific ADC<\/strong> and <strong>SKB264 TROP2 ADC<\/strong> provide <strong>first\u2011in\u2011class\/best\u2011in\u2011class<\/strong> potential vs. crowded monospecific ADC landscape.<\/li>\n\n\n\n<li><strong>Capital Markets Strategy:<\/strong> HKG:6990 listing provides <strong>RMB\/HKD financing flexibility<\/strong>; adjusted loss narrowing supports <strong>valuation re\u2011rating<\/strong> from clinical\u2011stage to commercial\u2011stage multiples; potential <strong>secondary offering<\/strong> or <strong>partnership monetization<\/strong> (ex\u2011China rights) to fund Phase III pipeline.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding revenue growth projections, margin expansion timelines, and pipeline advancement expectations for Kelun\u2011Biotech. Actual results may differ due to NRDL pricing pressures, competitive dynamics in the ADC market, and clinical trial outcomes for next\u2011generation modalities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced annual results for 2025, with full\u2011year revenue&#8230;<\/p>\n","protected":false},"author":1,"featured_media":61204,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[27,971,1832],"class_list":["post-61202","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-6990","tag-kelun-biotech-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kelun\u2011Biotech Reports 2025 Revenue RMB 2.06 Billion \u2013 Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced annual results for 2025, with full\u2011year revenue reaching RMB 2.058 billion (\u2248\u202fUS$298 million) and gross profit of RMB 1.479 billion (\u2248\u202fUS$214 million), while advancing a differentiated R&amp;D pipeline spanning bispecific ADCs, radionuclide drug conjugates (RDCs), immune\u2011stimulating ADCs (iADCs), and degrader\u2011antibody conjugates (DACs) \u2013 positioning the company for business transformation from clinical\u2011stage to commercial\u2011stage biopharma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61202\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kelun\u2011Biotech Reports 2025 Revenue RMB 2.06 Billion \u2013 Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification\" \/>\n<meta property=\"og:description\" content=\"Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced annual results for 2025, with full\u2011year revenue reaching RMB 2.058 billion (\u2248\u202fUS$298 million) and gross profit of RMB 1.479 billion (\u2248\u202fUS$214 million), while advancing a differentiated R&amp;D pipeline spanning bispecific ADCs, radionuclide drug conjugates (RDCs), immune\u2011stimulating ADCs (iADCs), and degrader\u2011antibody conjugates (DACs) \u2013 positioning the company for business transformation from clinical\u2011stage to commercial\u2011stage biopharma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61202\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-25T04:48:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2501.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61202#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61202\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kelun\u2011Biotech Reports 2025 Revenue RMB 2.06 Billion \u2013 Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification\",\"datePublished\":\"2026-03-25T04:48:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61202\"},\"wordCount\":495,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61202#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2501.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 6990\",\"Kelun-Biotech Biopharmaceutical\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61202#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61202\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61202\",\"name\":\"Kelun\u2011Biotech Reports 2025 Revenue RMB 2.06 Billion \u2013 Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61202#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61202#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2501.webp\",\"datePublished\":\"2026-03-25T04:48:36+00:00\",\"description\":\"Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced annual results for 2025, with full\u2011year revenue reaching RMB 2.058 billion (\u2248\u202fUS$298 million) and gross profit of RMB 1.479 billion (\u2248\u202fUS$214 million), while advancing a differentiated R&D pipeline spanning bispecific ADCs, radionuclide drug conjugates (RDCs), immune\u2011stimulating ADCs (iADCs), and degrader\u2011antibody conjugates (DACs) \u2013 positioning the company for business transformation from clinical\u2011stage to commercial\u2011stage biopharma.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61202#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61202\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61202#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2501.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2501.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kelun\u2011Biotech Reports 2025 Revenue RMB 2.06 Billion \u2013 Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61202#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kelun\u2011Biotech Reports 2025 Revenue RMB 2.06 Billion \u2013 Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kelun\u2011Biotech Reports 2025 Revenue RMB 2.06 Billion \u2013 Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced annual results for 2025, with full\u2011year revenue reaching RMB 2.058 billion (\u2248\u202fUS$298 million) and gross profit of RMB 1.479 billion (\u2248\u202fUS$214 million), while advancing a differentiated R&D pipeline spanning bispecific ADCs, radionuclide drug conjugates (RDCs), immune\u2011stimulating ADCs (iADCs), and degrader\u2011antibody conjugates (DACs) \u2013 positioning the company for business transformation from clinical\u2011stage to commercial\u2011stage biopharma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61202","og_locale":"en_US","og_type":"article","og_title":"Kelun\u2011Biotech Reports 2025 Revenue RMB 2.06 Billion \u2013 Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification","og_description":"Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced annual results for 2025, with full\u2011year revenue reaching RMB 2.058 billion (\u2248\u202fUS$298 million) and gross profit of RMB 1.479 billion (\u2248\u202fUS$214 million), while advancing a differentiated R&D pipeline spanning bispecific ADCs, radionuclide drug conjugates (RDCs), immune\u2011stimulating ADCs (iADCs), and degrader\u2011antibody conjugates (DACs) \u2013 positioning the company for business transformation from clinical\u2011stage to commercial\u2011stage biopharma.","og_url":"https:\/\/flcube.com\/?p=61202","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-25T04:48:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2501.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61202#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61202"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kelun\u2011Biotech Reports 2025 Revenue RMB 2.06 Billion \u2013 Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification","datePublished":"2026-03-25T04:48:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61202"},"wordCount":495,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=61202#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2501.webp","keywords":["Finanical Reports","HKG: 6990","Kelun-Biotech Biopharmaceutical"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61202#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61202","url":"https:\/\/flcube.com\/?p=61202","name":"Kelun\u2011Biotech Reports 2025 Revenue RMB 2.06 Billion \u2013 Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=61202#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=61202#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2501.webp","datePublished":"2026-03-25T04:48:36+00:00","description":"Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced annual results for 2025, with full\u2011year revenue reaching RMB 2.058 billion (\u2248\u202fUS$298 million) and gross profit of RMB 1.479 billion (\u2248\u202fUS$214 million), while advancing a differentiated R&D pipeline spanning bispecific ADCs, radionuclide drug conjugates (RDCs), immune\u2011stimulating ADCs (iADCs), and degrader\u2011antibody conjugates (DACs) \u2013 positioning the company for business transformation from clinical\u2011stage to commercial\u2011stage biopharma.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61202#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61202"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=61202#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2501.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2501.webp","width":1080,"height":608,"caption":"Kelun\u2011Biotech Reports 2025 Revenue RMB 2.06 Billion \u2013 Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61202#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kelun\u2011Biotech Reports 2025 Revenue RMB 2.06 Billion \u2013 Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2501.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61202"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61202\/revisions"}],"predecessor-version":[{"id":61205,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61202\/revisions\/61205"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/61204"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}